World Leading 3D Gait Analysis and Biomechanics Expert Dr. Reed Ferber Joins Biotricity Board of Advisors
MARCH 27, 2017 | BY BIOTRICITY
REDWOOD CITY, Calif., March 27, 2017 — Biotricity Inc. (OTCQB:BTCY), a healthcare technology company committed to delivering innovative, medically-relevant biometric remote monitoring solutions, today announced that Dr. Reed Ferber Ph.D., ATC, will join its Board of Advisors (BOA). As a recognized visionary in gait biomechanics and bioengineering, Dr. Ferber specializes in the research and clinical treatment of lower extremity injuries and is internationally recognized as an expert in running injuries, clinical biomechanics, and rehabilitation research. Based on his nearly twenty-five years of experience and significant research accomplishments, Dr. Ferber will work with Biotricity to develop new motion compensation algorithms that reduce noise artifact for future products.
“I am thrilled to join Biotricity’s board of advisors and help them develop additional medical-grade devices that significantly improve patients’ outcomes and reduce response times,” said Ferber. “Biotricity’s next-generation remote monitoring devices can be instrumental in helping to identify, develop, and optimize the treatment of disease and rehabilitation protocols.”
Dr. Ferber is an Associate Professor in the Faculty of Kinesiology and the Director and Chief Scientific Officer of the Running Injury Clinic at the University of Calgary. An award-winning teacher, he currently holds NSERC Discovery and Idea-2-Innovation grants and an NSERC Accelerator Award, which is given to only 125 scientists each year who are “highly original and innovative with ground-breaking advances in their area.” Dr. Ferber has worked with world-leading wearable technology companies such as Garmin, Fitbit, and Orpyx and has extensively published research to validate and develop novel algorithms related to injury prediction and prevention. He holds a Ph.D. in sports medicine and gait biomechanics from the University of Oregon and is a board certified athletic trainer.
“We look forward to leveraging Dr. Ferber’s clinical and diagnostic expertise and to applying his rich experience in motion and motion compensation order to develop additional medical-grade devices,” said Waqaas Al-Siddiq, Biotricity founder and CEO. “His pioneering work on biomechanical motion analysis and wearable devices combined with his interest in preventative care, will be valuable to our advisory board where he will collaborate with other talented and accomplished members to help drive our strategic vision of advancing the capabilities of remote biometric technology to improve the lives of people with chronic medical conditions.”
Biotricity’s goal is to meet the needs of physicians and individuals looking to bridge the gap between diagnostic care and disease management by developing multiple solutions for chronic illnesses. By designing monitoring devices paired with chronic care management tools, Biotricity will improve patient compliance and empower the individual to take better care of their health. Consisting of an IoT-connected device, ECG-analysis software, and comprehensive remote monitoring center access, the Company’s Bioflux product is a remote cardiac monitoring system that physicians will use for testing and diagnostic care. The device generates customized reports tailored to a physician’s individual patient for diagnostic purposes.
In the future, Biotricity will develop additional solutions for chronic illnesses, including sleep apnea, diabetes, prenatal care, etc. by designing monitoring devices paired with chronic care management tools to improve patient compliance and empower the individual to take better care of their health. This is particularly true of managing heart-related illnesses because without any feedback mechanism or continuous monitoring, patients often fail to adhere to doctors’ medical directives, dietary changes, exercise regiments, and lifestyle alterations.
About Biotricity Inc.
Biotricity’s mission is to revolutionize chronic care management by developing innovative solutions that bridge the gap between diagnostic care and disease management. A medical technology company, Biotricity is focused on delivering innovative, remote biometric monitoring solutions to the healthcare and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. Biotricity’s R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.